title: Clinical Application of Recombinant Human Endostatin in Postoperative Early Complementary Therapy on Patients with Non-small Cell Lung Cancer in Chinese Mainland.
abstract: OBJECTIVE
  To explore the clinical application of recombinant human endostatin (Endostar) in the treatment of patients with non-small cell lung cancer (NSCLC) in Chinese mainland.
  
  
  METHODS
  A total of 75 patients diagnosed as NSCLC were randomly divided into control group (37 cases) and treatment group (38 cases). Control group was treated with postoperative complementary chemotherapy containing two-agent platinum protocol on postoperative d21, 3 weeks as a cycle, for totally 4~6 cycles. On this basis, treatment group was added with Endostar 7.5 mg/m2 on postoperative d8~9, 3~4 h/time, qd, 14 weeks as a cycle, for totally 4 cycles. The interval between every two cycles was 7 d. The 5-year progression-free survival (PFS), 5-year survival time and complications in both groups were observed.
  
  
  RESULTS
  Compared with control group, the average PFS increased evidently in treatment group by 9.8 months (41.6 months vs. 31.8 months), and there was significant difference (P<0.05). And the median PFS was 42.5 months in treatment group, obviously longer than that in control group (33.7 months) by 8.8 months (P<0.05). Additionally, the 5-year overall survival rate (OS), average survival time and median survival time (MST) were 47.4%, 50.1 months and 59.3 months in treatment group, significantly higher than the 29.7%, 42.1 months and 43.5 months in control group (P<0.05). Only 1 patient showed poor healing of surgical wound in treatment group, but no surgery-associated complication was found in control group. Moreover, the postoperative complementary therapy-connected complication rates were 63.2% (24/38) and 59.5% (22/37) in treatment group and control group respectively, but there was no significant difference (P>0.05).
  
  
  CONCLUSIONS
  The application of Endostar combined with sensitive platinum-contained chemotherapeutic agents in the postoperative complementary chemotherapy can be widely used in clinic because it can significantly prolong the long-term survival time of patients with NSCLC.
authors.affiliation: Weifang Medical University, Weifang, China E-mail : qzang2005@sina.com.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Zhu
authors.forename: Qi
authors.initials: Q
authors.lastname: Zang
authors.forename: Zhong-Min
authors.initials: ZM
authors.lastname: Jiang
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Ming
authors.initials: M
authors.lastname: Cao
authors.forename: Gong-Zhang
authors.initials: GZ
authors.lastname: Su
authors.forename: Tian-Chang
authors.initials: TC
authors.lastname: Zhen
authors.forename: Xiao-Tian
authors.initials: XT
authors.lastname: Zhang
authors.forename: Ning-Bo
authors.initials: NB
authors.lastname: Sun
authors.forename: Cheng
authors.initials: C
authors.lastname: Zhao
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000556:secondary / Q000628:therapy; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000556:secondary / Q000628:therapy; D016022:Case-Control Studies; D002681:China; D003131:Combined Modality Therapy; D000529:Complementary Therapies; D043169:Endostatins / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D011182:Postoperative Care; D011183:Postoperative Complications; D011379:Prognosis; D011994:Recombinant Proteins / Q000008:administration & dosage*; D015996:Survival Rate
chemical_list: D043169:Endostatins; D011994:Recombinant Proteins